As of today’s session, Verve stock price holds near $13, supported by bullish sentiment in gene-editing stocks. Technical indicators show a potential breakout if it stays above its 50-day MA. Traders watch closely for any news from FDA filings that could shift short-term market projections. Our free stock report includes 3 warning signs investors should be aware of before investing in Verve Therapeutics. Read for free now . Pharma giant Eli Lilly (LLY) is reportedly in advanced talks to acquire gene editing company Verve Therapeutics (VERV) , the Financial Times reported. Verve Therapeutics stock rallied 75% in Mondayâs after-hours trading in reaction to the news. If finalized, the deal would boost Eli Lillyâs pipeline of experimental drugs. Verve stock price stability above $12.90 is fueling optimism among swing traders. Moving average convergence-divergence signals are turning bullish in short-term technical models.
